[Pharmacokinetics of vancomycin in children hospitalized in a critical care unit]

Area of Science:

• Pediatric Intensive Care
• Pharmacokinetics and Pharmacodynamics
• Antimicrobial Therapy

Context:

• Vancomycin is a critical antibiotic for treating staphylococcal infections in children.
• Optimizing vancomycin dosing in pediatric patients is essential for effective treatment and minimizing resistance.
• Current monitoring strategies may not adequately capture therapeutic efficacy in critically ill children.

Purpose:

• To evaluate the pharmacokinetic/pharmacodynamic (PK/PD) parameters of vancomycin in children admitted to the Pediatric Intensive Care Unit (PICU).
• To assess the achievement of therapeutic targets, specifically the area under the curve of drug exposure over the 24-hour period divided by the minimum inhibitory concentration (ABC 24 h/MIC), in this pediatric population.
• To determine the proportion of children achieving optimal vancomycin exposure based on PK/PD targets.

Summary:

• Eighty-four children receiving vancomycin (40 mg/kg/day) in the PICU were studied retrospectively.
• While 49% had basal vancomycin levels within the therapeutic range (5-15 μg/mL), only 54% achieved the target ABC 24 h/MIC of > 400 mg*h/L.
• A significant proportion of children may be exposed to sub-therapeutic vancomycin doses, highlighting potential limitations in standard dosing and monitoring.

Impact:

• The findings suggest that standard vancomycin dosing may be insufficient for achieving therapeutic targets in critically ill children.
• Implementing tailored antimicrobial treatment strategies based on PK/PD monitoring is recommended for optimizing vancomycin therapy in pediatric patients.
• This study underscores the importance of individualized vancomycin dosing and therapeutic drug monitoring in the PICU setting to improve patient outcomes.